Protocol Ledger

NCT05439356 · Phase III · COMPLETED

Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)

Interventional Phase III clinical trial protocol NCT05439356 sponsored by Beijing Tiantan Hospital in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-11 Enrollment: 8,343 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05439356
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)8,343 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05439356
Protocol FieldVerified Registry Value
NCT IdentifierNCT05439356
Consolidated Lead SponsorBeijing Tiantan Hospital
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment8,343 participants (ACTUAL)
Registered Start Date2022-08-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI